NasdaqCM:CPRX

Stock Analysis Report

Executive Summary

Catalyst Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases.


Snowflake Analysis

Exceptional growth potential with flawless balance sheet.

Share Price & News

How has Catalyst Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: CPRX's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-4.3%

CPRX

-1.5%

US Biotechs

-4.2%

US Market


1 Year Return

61.0%

CPRX

10.2%

US Biotechs

14.0%

US Market

Return vs Industry: CPRX exceeded the US Biotechs industry which returned 12.6% over the past year.

Return vs Market: CPRX exceeded the US Market which returned 17.8% over the past year.


Shareholder returns

CPRXIndustryMarket
7 Day-4.3%-1.5%-4.2%
30 Day23.4%3.9%-1.8%
90 Day4.9%3.4%2.6%
1 Year61.0%61.0%11.1%10.2%16.3%14.0%
3 Year334.5%334.5%19.6%16.4%43.2%34.0%
5 Year34.5%34.5%1.3%-3.4%65.9%47.6%

Price Volatility Vs. Market

How volatile is Catalyst Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Catalyst Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: CPRX ($5.21) is trading below our estimate of fair value ($10.02)

Significantly Below Fair Value: CPRX is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: CPRX is poor value based on its PE Ratio (56.7x) compared to the Biotechs industry average (20.1x).

PE vs Market: CPRX is poor value based on its PE Ratio (56.7x) compared to the US market (18.2x).


Price to Earnings Growth Ratio

PEG Ratio: CPRX is poor value based on its PEG Ratio (1.8x)


Price to Book Ratio

PB vs Industry: CPRX is overvalued based on its PB Ratio (6.9x) compared to the US Biotechs industry average (3.3x).


Next Steps

Future Growth

How is Catalyst Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

31.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: CPRX's forecast earnings growth (31.3% per year) is above the savings rate (1.7%).

Earnings vs Market: CPRX's earnings (31.3% per year) are forecast to grow faster than the US market (14.1% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: CPRX's revenue (21.5% per year) is forecast to grow faster than the US market (7.6% per year).

High Growth Revenue: CPRX's revenue (21.5% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: CPRX's Return on Equity is forecast to be very high in 3 years time (43.4%).


Next Steps

Past Performance

How has Catalyst Pharmaceuticals performed over the past 5 years?

0.7%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: CPRX has high quality earnings.

Growing Profit Margin: CPRX became profitable in the past.


Past Earnings Growth Analysis

Earnings Trend: CPRX has become profitable over the past 5 years, growing earnings by 0.7% per year.

Accelerating Growth: CPRX has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: CPRX has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (66.2%).


Return on Equity

High ROE: CPRX's Return on Equity (12.1%) is considered low.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Catalyst Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: CPRX's short term assets ($90.6M) exceed its short term liabilities ($18.0M).

Long Term Liabilities: CPRX's short term assets ($90.6M) exceed its long term liabilities ($725.7K).


Debt to Equity History and Analysis

Debt Level: CPRX is debt free.

Reducing Debt: CPRX has not had any debt for past 5 years.


Balance Sheet

Inventory Level: CPRX has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if CPRX's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: CPRX is profitable, therefore cash runway is not a concern.

Forecast Cash Runway: CPRX is profitable, therefore cash runway is not a concern.


Next Steps

Dividend

What is Catalyst Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.5%markettop25%3.8%industryaverage2.1%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate CPRX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate CPRX's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CPRX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CPRX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CPRX's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.7yrs

Average management tenure


CEO

Pat McEnany (72yo)

18.1yrs

Tenure

US$3,461,504

Compensation

Mr. Patrick J. McEnany, also known as Pat, Co-Founded Catalyst Pharmaceutical Partners Inc. in January 2002 and has been its Chairman and President since March 2006 and also its Chief Executive Officer sin ...


CEO Compensation Analysis

Compensation vs Market: Pat's total compensation ($USD3.46M) is above average for companies of similar size in the US market ($USD1.67M).

Compensation vs Earnings: Pat's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Patrick McEnany
Co-Founder18.1yrsUS$3.46m4.63% $23.4m
Steven Miller
COO & Chief Scientific Officer9.1yrsUS$1.66m0.64% $3.2m
Gary Ingenito
Chief Medical Officer & Head of Regulatory Affairs4.7yrsUS$1.67mno data
Alicia Grande
VP, Treasurer & CFO8.2yrsUS$523.85k0.38% $1.9m
Brian Elsbernd
Chief Legal & Compliance Officer4yrsUS$353.27kno data
Jeff Carmen
Senior Vice President of Sales & Marketing1.5yrsno datano data
Daniel Brennan
Chief Commercial Officer1.7yrsno data0.0030% $15.2k
Philip Schwartz
Corporate Secretary0yrsno datano data
Charles Gorodetzky
Consultant0yrsno datano data

4.7yrs

Average Tenure

60yo

Average Age

Experienced Management: CPRX's management team is considered experienced (4.7 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Patrick McEnany
Co-Founder18.1yrsUS$3.46m4.63% $23.4m
Philip Coelho
Independent Director17.3yrsUS$216.51k0.21% $1.1m
David Tierney
Independent Director17.3yrsUS$217.01k0.30% $1.5m
Donald Denkhaus
Independent Director5yrsUS$220.01k0.22% $1.1m
Charles O'Keeffe
Lead Independent Director8.6yrsUS$238.51k0.54% $2.7m
Richard Daly
Independent Director5yrsUS$211.01kno data
Eugene Laska
Member of Scientific Advisory Board0yrsno datano data
Robert Fechtner
Member of Scientific Advisory Board0yrsno datano data
Jonathan Brodie
Chairman of Scientific Advisory Board0yrsno datano data
Richard Silverman
Member of Scientific Advisory Board9.3yrsno datano data

9.3yrs

Average Tenure

72.5yo

Average Age

Experienced Board: CPRX's board of directors are considered experienced (9.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 3%.


Top Shareholders

Company Information

Catalyst Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Catalyst Pharmaceuticals, Inc.
  • Ticker: CPRX
  • Exchange: NasdaqCM
  • Founded: 2002
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$505.961m
  • Shares outstanding: 103.05m
  • Website: https://www.catalystpharma.com

Number of Employees


Location

  • Catalyst Pharmaceuticals, Inc.
  • 355 Alhambra Circle
  • Suite 1250
  • Coral Gables
  • Florida
  • 33134
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CPRXNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDNov 2006
CN2DB (Deutsche Boerse AG)YesCommon StockDEEURNov 2006

Biography

Catalyst Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with lambert-eaton myasthenic syndrome in the United States. The company also develops Firdapse, which is in various clinical trials for the treatment of patients with congenital myasthenic syndrome, anti-MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3. It has license agreements with New York University, the Feinstein Institute for Medical Research, and BioMarin Pharmaceutical Inc.; and collaboration agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/25 00:20
End of Day Share Price2020/02/24 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.